| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MAO-B (monoamine oxidase B), mTORC1/2, and Helicobacter pylori. Dihydroevocarpine exhibits more potent inhibitory effects against MAO-B compared to MAO-A. It induces cytotoxicity by suppressing mTORC1/2 activity. It also shows potent anti-Helicobacter pylori activity.
|
|---|---|
| ln Vitro |
Dihydroevocarpine exhibits potent inhibitory effects against MAO-B. It shows potent anti-Helicobacter pylori activity with an MIC value of 10-20 μg/mL. Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia cells by suppressing mTORC1/2 activity. The compound modulates neurotransmitter systems and inhibits pro-inflammatory cytokines.
|
| ln Vivo |
No detailed in vivo activity data are publicly available for dihydroevocarpine. As an MAO-B inhibitor and mTOR inhibitor, its in vivo effects would be expected to be related to these mechanisms of action.
|
| Enzyme Assay |
In vitro enzyme assays for dihydroevocarpine are performed to evaluate its inhibitory activity against MAO-B and MAO-A. The enzymes are incubated with substrates and varying concentrations of the compound. The inhibition of enzyme activity is measured, and IC50 values are calculated.
|
| Cell Assay |
In vitro cell-based assays are conducted to evaluate the effects of dihydroevocarpine on cell viability, inflammation, and neurotransmitter systems. Cells are treated with dihydroevocarpine, and cell viability is assessed using standard assays. The compound's ability to inhibit pro-inflammatory cytokines is measured by ELISA. Its effects on neurotransmitter systems are assessed by measuring neurotransmitter levels or receptor activity.
|
| Animal Protocol |
In vivo animal studies with dihydroevocarpine would be conducted in models of pain, inflammation, or cancer to evaluate its therapeutic potential. The compound could be administered via oral or intraperitoneal routes. Its effects on pain relief, inflammation, and tumor growth would be assessed.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for dihydroevocarpine. As a natural alkaloid, its ADME properties would be characterized in standard preclinical studies.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for dihydroevocarpine. As a natural product, it is generally considered to have low toxicity, but comprehensive toxicological studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Reports indicate that rutin tetrahydroluteolin contains dihydroecocaine, and relevant data is available for reference.
Dihydroevocarpine is a natural quinolone alkaloid from Evodia rutaecarpa that exhibits MAO-B inhibitory, anti-Helicobacter pylori, and anticancer activities. It induces cytotoxicity in acute myeloid leukemia by suppressing mTORC1/2 activity and modulates neurotransmitter systems and inflammation. The compound is a valuable research tool for studying MAO-B inhibition, inflammation, and cancer. It is not approved for human therapeutic use and is strictly for research purposes. |
| Molecular Formula |
C23H35NO
|
|---|---|
| Molecular Weight |
341.53
|
| Exact Mass |
341.271
|
| CAS # |
15266-35-0
|
| PubChem CID |
5322031
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
447.0±45.0 °C at 760 mmHg
|
| Melting Point |
68-69℃
|
| Flash Point |
149.1±18.1 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.514
|
| LogP |
8.22
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
25
|
| Complexity |
414
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC1=CC(=O)C2=CC=CC=C2N1C
|
| InChi Key |
DWHCRAGHDDLXEM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H35NO/c1-3-4-5-6-7-8-9-10-11-12-13-16-20-19-23(25)21-17-14-15-18-22(21)24(20)2/h14-15,17-19H,3-13,16H2,1-2H3
|
| Chemical Name |
1-methyl-2-tridecylquinolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 16.67 mg/mL (48.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.67 mg/mL (4.89 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9280 mL | 14.6400 mL | 29.2800 mL | |
| 5 mM | 0.5856 mL | 2.9280 mL | 5.8560 mL | |
| 10 mM | 0.2928 mL | 1.4640 mL | 2.9280 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
